Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL PITUITARY CANCER MARKET, BY CANCER TYPE
6.1. Overview
6.2. Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Growth Hormone-Secreting Tumor
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Prolactin-Secreting Tumor
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Thyroid-Stimulating Hormone-Secreting Tumor
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL PITUITARY CANCER MARKET, BY TREATMENT TYPE
7.1. Overview
7.2. Surgery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1. Endoscopic Transnasal Transsphenoidal
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.2. Craniotomy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Radiation Therapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.1. Stereotactic Radiosurgery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.2. External Beam Radiation
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.3. Intensity Modulated Radiation Therapy (IMRT)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.4. Proton Beam Therapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Chemotherapy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL PITUITARY CANCER MARKET, BY END USER
8.1. Overview
8.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Specialty Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL PITUITARY CANCER MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Pituitary Cancer Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Pituitary Cancer Market
10.7. Key Developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
11. COMPANY PROFILES
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Celgene Corporation
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Astellas Pharma Inc.
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Merck & Co., Inc.
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Pfizer Inc.
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. AstraZeneca
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Mylan NV
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Johnson & Johnson Services, Inc.
11.11.1. Company Overview
11.11.2. Product Overview
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Onxeo
11.12.1. Company Overview
11.12.2. Product Overview
11.12.3. Financial Overview
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Ipsen Pharmaceuticals
11.13.1. Company Overview
11.13.2. Product Overview
11.13.3. Financial Overview
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Salix Pharmaceuticals, Inc.
11.14.1. Company Overview
11.14.2. Product Overview
11.14.3. Financial Overview
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. Strides Pharma Science Limited
11.15.1. Company Overview
11.15.2. Product Overview
11.15.3. Financial Overview
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
11.16. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL PITUITARY CANCER MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL PITUITARY CANCER MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL PITUITARY CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10 US: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 11 US: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 12 US: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 13 CANADA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 14 CANADA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 15 CANADA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 LATIN AMERICA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 17 LATIN AMERICA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 18 LATIN AMERICA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 19 EUROPE: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 21 EUROPE: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL PITUITARY CANCER MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL PITUITARY CANCER MARKET
FIGURE 4 GLOBAL PITUITARY CANCER MARKET SHARE, BY CANCER TYPE, 2020 (%)
FIGURE 5 GLOBAL PITUITARY CANCER MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
FIGURE 6 GLOBAL PITUITARY CANCER MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL PITUITARY CANCER MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: PITUITARY CANCER MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: PITUITARY CANCER MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL PITUITARY CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 AMGEN INC..: KEY FINANCIALS
FIGURE 15 AMGEN INC.: SEGMENTAL REVENUE
FIGURE 16 AMGEN INC.: REGIONAL REVENUE
FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 18 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 19 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE
FIGURE 20 CELGENE CORPORATION: KEY FINANCIALS
FIGURE 21 CELGENE CORPORATION: SEGMENTAL REVENUE
FIGURE 22 CELGENE CORPORATION: REGIONAL REVENUE
FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 26 ASTELLAS PHARMA INC.: KEY FINANCIALS
FIGURE 27 ASTELLAS PHARMA INC.: SEGMENTAL REVENUE
FIGURE 28 ASTELLAS PHARMA INC.: REGIONAL REVENUE
FIGURE 29 MERCK & CO., INC.: KEY FINANCIALS
FIGURE 30 MERCK & CO., INC.: SEGMENTAL REVENUE
FIGURE 31 MERCK & CO., INC.: REGIONAL REVENUE
FIGURE 32 NOVARTIS AG: KEY FINANCIALS
FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 34 NOVARTIS AG: REGIONAL REVENUE
FIGURE 35 PFIZER INC.: KEY FINANCIALS
FIGURE 36 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 37 PFIZER INC.: REGIONAL REVENUE
FIGURE 38 ASTRAZENECA: KEY FINANCIALS
FIGURE 39 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 40 ASTRAZENECA: REGIONAL REVENUE
FIGURE 41 MYLAN N.V.: KEY FINANCIALS
FIGURE 42 MYLAN N.V.: SEGMENTAL REVENUE
FIGURE 43 MYLAN N.V.: REGIONAL REVENUE
FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE
FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE
FIGURE 47 ONXEO: KEY FINANCIALS
FIGURE 48 ONXEO: SEGMENTAL REVENUE
FIGURE 49 ONXEO: REGIONAL REVENUE
FIGURE 50 IPSEN PHARMACEUTICALS: KEY FINANCIALS
FIGURE 51 IPSEN PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 52 IPSEN PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 53 SALIX PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 54 SALIX PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 55 SALIX PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 56 STRIDES PHARMA SCIENCE LIMITED: KEY FINANCIALS
FIGURE 57 STRIDES PHARMA SCIENCE LIMITED: SEGMENTAL REVENUE
FIGURE 58 STRIDES PHARMA SCIENCE LIMITED: REGIONAL REVENU
